Sherbrooke Park Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sherbrooke Park Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,652	Closed	-$739K	–	233
2025 Q3	$739K	Sell	13,652 -11,026	-45%	-$631K	0.34%	75
2025 Q2	$1.36M	Buy	+24,678	New	+$1.45M	0.59%	11
2025 Q1	–	Sell	-5,510	Closed	-$362K	–	632
2024 Q4	$362K	Buy	+5,510	New	+$369K	0.12%	319
2024 Q3	–	Sell	-7,488	Closed	-$616K	–	930
2024 Q2	$616K	Buy	7,488 +2,820	+60%	+$235K	0.11%	322
2024 Q1	$408K	Buy	+4,668	New	+$418K	0.08%	440
2023 Q4	–	Sell	-12,515	Closed	-$1.11M	–	472
2023 Q3	$1.11M	Buy	+12,515	New	+$1.11M	0.35%	86

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sherbrooke Park Advisers's BMRN Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 13,652 shares — an estimated $739K sold.

Sherbrooke Park Advisers first reported a position in BMRN in Q3 2023 and held it in 6 quarters. The position peaked at $1.36M in Q2 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Sherbrooke Park Advisers reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 13,652 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $739K.
Sherbrooke Park Advisers first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Sherbrooke Park Advisers's BioMarin Pharmaceuticals position peaked at $1.36M in Q2 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.